165 related articles for article (PubMed ID: 12972520)
41. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
[TBL] [Abstract][Full Text] [Related]
43. Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Burris HA; Jones SF; Shipley D; Meluch AA; Greco FA; Barton JH; Yardley DA; Hainsworth JD
Cancer Invest; 2010 May; 28(4):408-12. PubMed ID: 20210519
[TBL] [Abstract][Full Text] [Related]
44. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
45. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
46. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
El-Helw L; Coleman RE
Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
[TBL] [Abstract][Full Text] [Related]
47. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
48. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Kaufmann M; Maass N; Costa SD; Schneeweiss A; Loibl S; Sütterlin MW; Schrader I; Gerber B; Bauer W; Wiest W; Tomé O; Distelrath A; Hagen V; Kleine-Tebbe A; Ruckhaeberle E; Mehta K; von Minckwitz G;
Eur J Cancer; 2010 Dec; 46(18):3184-91. PubMed ID: 20797843
[TBL] [Abstract][Full Text] [Related]
49. Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study.
Maisano R; Caristi N; Mare M; Mafodda A; Carboni R; Montalto E; Iorfida M; Nardi M
Anticancer Res; 2005; 25(6C):4513-7. PubMed ID: 16334135
[TBL] [Abstract][Full Text] [Related]
50. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
51. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Levy C; Fumoleau P
Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
[TBL] [Abstract][Full Text] [Related]
52. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
[TBL] [Abstract][Full Text] [Related]
54. [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Liu X; Song S; Guan Z; Wu S; Duan Y; Yu J; Yang L
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):71-3. PubMed ID: 11977645
[TBL] [Abstract][Full Text] [Related]
55. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
[TBL] [Abstract][Full Text] [Related]
56. Capecitabine in elderly patients with metastatic breast cancer.
De Sanctis R; Quadrini S; Longo F; Lapadula V; Restuccia R; Del Signore E; De Filippis L; Stumbo L; Gori B; Bianco V; Speranza I; Basile ML; Di Seri M
Tumori; 2012; 98(3):303-7. PubMed ID: 22825504
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Wang Y; Yang H; Wei JF; Meng L
Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
[TBL] [Abstract][Full Text] [Related]
58. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
[TBL] [Abstract][Full Text] [Related]
59. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
[TBL] [Abstract][Full Text] [Related]
60. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S
J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
